Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Purdue University
Headquarters: West Lafayette, IN, United States of America
Website: http://www.purdue.edu
Year Founded: 1869
Status: Non-biopharma
Biopharma related deals can be found by searching the organization's name in the Deals Module.
BioCentury | Apr 24, 2024
Product Development
Next-wave radiopharmaceuticals: insights from AACR
Fusion added to view of ɑ-emitters in lutetium-experienced patients, as Novartis, RayzeBio gave peeks at programs with broad indication potential
BioCentury | Feb 10, 2024
Discovery & Translation
Science spotlight: Moonlight’s enhanced T cells; plus a HUNK inhibitor and more
BioCentury’s roundup of translational innovations
BioCentury | Aug 31, 2023
Finance
Aug. 31 Quick Takes: Sage downsizes, reveals executive departures
Plus: CCM launches with $25M+ and updates from Kangpu, Clock Bio, MC2, Huadong and RabPharma
BioCentury | Mar 23, 2023
Management Tracks
Treco to succeed Bolte as CEO of Inozyme
Plus: Seagen’s Siegall to be CEO at Morphimmune and updates from Jasper, Vividion and more
BioCentury | Oct 20, 2022
Politics, Policy & Law
Biden builds case for bolstering biomanufacturing
Administration initiatives aim to revitalize domestic biomanufacturing
BioCentury | Apr 1, 2022
Discovery & Translation
An in vivo CAR T manufacturing implant; plus Seer, Kither and more
BioCentury’s roundup of translational news
BioCentury | Nov 24, 2021
Discovery & Translation
New mechanisms and modalities emerge for TIGIT
2021 ASH and SITC abstracts are low on data, high on innovation
BioCentury | Nov 19, 2020
Emerging Company Profile
Umoja launches with $53M round to test cell therapy cocktails that expand CAR T cells within patients
Emerging Company Profile: Umoja to test in vivo approach with first-in-human trial next year
BioCentury | Nov 7, 2020
Translation in Brief
Neoleukin’s ACE2 decoy protects hamsters from SARS-CoV-2; plus a circular RNA linked to diabetes and more
BioCentury’s roundup of translational news
Items per page:
1 - 10 of 88